Analysts think ADAP stock price could increase by 410%
May 08, 2025, 11:25 AM
-5.66%
What does ADAP do
Adaptimmune Therapeutics Plc, a commercial-stage cell therapy company based in Abingdon, Oxfordshire, focuses on novel T-cell therapies for cancer, including afamitresgene autoleucel and Lete-cel. The company employs 449 people and went public on May 6, 2015.
10 analysts think ADAP stock price will increase by 409.83%. The current median analyst target is $1.53 compared to a current stock price of $0.30. The lowest analysts target is $1.01 and the highest analyst target is $3.15.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.